Contrast agent puts new light on diagnosing breast cancer

User rating: 4 / 5 after 5 vote(s)

Hydroxyapatite crystals (pseudo-colored in purple) like those found in human breast cancer are detected with high sensitivity using an optical contrast reagent and invisible near-infrared fluorescent light. Photo courtesy of Dr. John Frangioni
Hydroxyapatite crystals (pseudo-colored in purple), like those found in human breast cancer, are detected with high sensitivity using an optical contrast reagent and invisible near-infrared fluorescent light. Photo courtesy of Dr. John Frangioni

Harvard Medical School researchers are working on a new, simpler way to distinguish malignant tumors from non-cancerous masses when screening for breast cancer.


Full story »
All News summaries from Medicine & Health news
All News summaries for March 26, 2007

5 things you didn't know about... buying medication online

9 hours ago | User rating: not rated yet
Cynthia Reilly, director of the practice development division of the American Society of Health-Systems Pharmacists, offers advice for shopping online:

Scientists go chatting to hear kids' drug concerns

9 hours ago | User rating: not rated yet
(AP) -- It's nothing to LOL about. Students these days often have ready access to marijuana, alcohol and tobacco but they don't feel comfortable talking about the ramifications. So, some of the nation's government ...

End-of-life discussions with physicians may have benefits for patients and caregivers

10 hours ago | User rating: not rated yet
Terminally ill patients who had end-of-life discussions with physicians were not more likely to experience emotional distress, received less aggressive medical care in their final week of life and had a better quality of ...

Older renal cancer patients appear to benefit from sorafenib treatment

10 hours ago | User rating: not rated yet
Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug equally well, according to a study published online October 7 in the Journal of the National Cancer Institute.

Use of medication for enlarged prostate not associated with increased risk of hip fracture

10 hours ago | User rating: not rated yet
Use of a class of medications for treating an enlarged prostate, known as 5-α reductase inhibitors, are not associated with an increased hip fracture risk, according to a study in the October 8 issue of JAMA.
Goto Archive PhysOrg Forum Goto Archive Video Goto Archive Editorials Goto Archive Free Magazines Goto Archive Newsletter

News Archive